Indian Drug Mfr sentenced to pay USD 50 million in fines

Fresenius Kabi Oncology (FKOL) was previously criminally charged by the United States with violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to FDA investigators.

506
Justice Court
Picture: Pixabay

Last Updated on March 24, 2021 by The Health Master

An Indian drug manufacturer has been sentenced to pay USD 50 million in fines and forfeiture after pleading guilty to concealing and destroying records prior to a 2013 US Food and Drug Administration (USFDA) plant inspection, the Department of Justice said.

Fresenius Kabi Oncology (FKOL) was previously criminally charged by the United States with violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to FDA investigators.


Also read related news: Indian Pharma Co to pay $50mn in fine for destroying records


FKOL owned and operated a manufacturing plant in Kalyani, West Bengal, that manufactured active pharmaceutical ingredients (APIs) used in various cancer drug products distributed to the United States.

As part of a criminal resolution with the Department of Justice, FKOL agreed to plead guilty to the misdemeanour offense.


Also read:

Drug alert: 14 out of 1204 samples declared as NSQ in…

Drug Price Control: A Double Edged Sword: Article

Wanted Drug Smuggler Kishan Singh Extradited from UK to India

FAQs – on Blood Pressure Monitoring Devices

Indian pharma firm develops Oral vaccine in capsule form for C-19…

Pharma Paint Launches Antiviral Paint: Must Read


Medicine Vaccine
Picture: Pixabay

US District Judge Jennifer A Dorsey accepted the company’s guilty plea and sentenced FKOL on Tuesday to pay a criminal fine of USD 30 million, forfeit an additional USD 20 million, and implement a compliance and ethics programme designed to prevent, detect, and correct violations of US law relating to FKOL’s manufacture of cancer drugs intended for terminally ill patients, a media release said.

“By concealing and destroying drug manufacturing records, FKOL undermined FDA’s regulatory authority and placed vulnerable consumers at risk,” said Acting Assistant Attorney General Brian M. Boynton of the Justice Department’s Civil Division.

Prior to a January 2013 FDA inspection of the Kalyani facility, FKOL plant management directed employees to remove certain records from the premises and delete other records from computers that would have revealed FKOL was manufacturing drug ingredients in contravention of FDA requirements.

Kalyani plant employees removed computers, hardcopy documents, and other materials from the plant and deleted spreadsheets that contained evidence of the plant’s noncompliant practices.

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner